Somatically mutated oncogenes, including enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), cAMP responsive element binding protein 1 (CREBBP), innate immune signal transduction adaptor MYD88, immunoglobulin-associated gene CD79B, Notch receptor 1 (NOTCH1), transcription factor B-cell lymphoma 6 (BCL6) proto-oncogene serine-threonine kinase PIM1, or B-cell lymphoma 2 (BCL2) play important roles in the pathogenesis of aggressive lymphomas [47,48]. This evidence concerns the gene BCL2 and lymphoma.